A multicenter study found that strict aliquoting of Locametz cold kits and controlled generator elutions safely increased gallium-68 prostate cancer imaging capacity while reducing diagnostic costs. The operational change centers on dividing kits and managing elution volumes to keep output within safety and workflow constraints. The report is notable for translating manufacturing process optimization into downstream clinical availability, a recurring bottleneck for PET/CT throughput. By expanding radiopharmaceutical capacity without changing the clinical scan indication, the study targets access rather than only performance. For nuclear medicine services, the practical takeaway is that small protocol changes in cold-kit utilization can materially affect the number of patients imaged each day.